)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ResMed
ResMed (RMD) investor relations material
ResMed Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary29 Oct, 2026
Executive summary
Q1 FY27 revenue was $1,414.8M, up 6% reported and 7% core constant currency; non-GAAP diluted EPS rose 14% to $2.91.
Sleep-portfolio demand and higher gross margin supported growth; MatrixCare proceeds and cash generation funded more than $1.0B in shareholder returns.
Financial highlights
GAAP net income was $418.4M versus $348.5M; GAAP diluted EPS was $2.92 versus $2.37.
Non-GAAP gross margin was 62.5%, up 50 bps; non-GAAP operating margin was 35.8%, down 30 bps, and non-GAAP net income was $418M versus $375M.
Operating cash flow was $422M and free cash flow was $374M, down 8% and 10% YoY, respectively.
MatrixCare's sale contributed a preliminary $62M pretax gain; GAAP operating income was $453.0M versus $446.5M.
Outlook and guidance
FY27 guidance remained unchanged: core constant-currency revenue growth of 5%-7%, reported revenue of $5.75B-$5.85B, and non-GAAP diluted EPS of $12.00-$12.25.
Revenue guidance includes an ~130 bps or $75M Astral impact and ~60 bps of FX pressure; excluding Astral, core constant-currency growth would be 6.3%-8.3%.
FY27 gross margin is expected to expand by low-double-digit bps, with a slight increase in operating margin; quarterly variability is expected.
FY27 capital returns are expected to exceed $1.85B; capex guidance is $160M-$180M. Q2 revenue is expected to follow typical mid-single-digit sequential seasonality.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ResMed
- Shareholders were asked to elect 10 directors, ratify KPMG, and approve executive pay.RMD
Proxy Filing - Ten director elections, KPMG ratification, and advisory votes anchor the ballot.RMDProxy Filing
- Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMDProxy Filing
- Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMDProxy Filing
- 2026 saw strong growth, strategic investments, and enhanced sustainability and governance.RMDStewardship presentation
- FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMDCorporate presentation
- Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook.RMDMorgan Stanley 24th Annual Global Healthcare Conference
- FY26 revenue grew 8% to $5.7B, with strong margins, digital innovation, and increased shareholder returns.RMDCorporate presentation
- Record FY26 growth, margin expansion, and $1.85B+ FY27 capital returns planned.RMDQ4 2026
Next ResMed earnings date
AGM 202618 Nov, 2026
ResMed
Next ResMed earnings date
AGM 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ResMed Inc. develops, manufactures, and markets medical devices, including equipment for the diagnosis and treatment of obstructive sleep apnea (OSA), related breathing disorders and other medical conditions connected to respiration. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.